Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice

Journal of the American Academy of Dermatology

Volumn 68, Issue 1, 2013, Pages 57-63

  Van Lümig, Paula P M ^a   Driessen, Rieke J B ^a   Kievit, Wietske ^a   Boezeman, Jan B M ^a   Van De Kerkhof, Peter C M ^a   De Jong, Elke M G J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

biologics; daily practice; etanercept; long term efficacy; method of analysis; psoriasis; registry

Indexed keywords

ETANERCEPT;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; LAST OBSERVATION CARRIED FORWARD; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MODIFIED NONRESPONDER IMPUTATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RATING SCALE; STATISTICAL ANALYSIS; SURVIVAL; TREATED ANALYSIS; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; PATIENT DROPOUTS; PROSPECTIVE STUDIES; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870933748     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.05.040     Document Type: Article

References (13)

1. C. Leonardi, B. Strober, A.B. Gottlieb, B.E. Elewski, J.P. Ortonne, and P. van de Kerkhof Long-term safety and efficacy of etanercept in patients with psoriasis: an open-label study J Drugs Dermatol 9 2010 928 937
2. K.A. Papp, Y. Poulin, R. Bissonnette, M. Bourcier, D. Toth, and L. Rosoph Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population J Am Acad Dermatol 66 2012 e33 e45 Epub 2010 Sep 17
3. S. Tyring, K.B. Gordon, Y. Poulin, R.G. Langley, A.B. Gottlieb, and M. Dunn Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 143 2007 719 726
4. M. Papoutsaki, M. Talamonti, A. Giunta, A. Costanzo, M. Ruzzetti, and M. Teoli The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab Dermatology 221 Suppl 1 2010 43 47
5. R. Schiffner, J. Schiffner-Rohe, M. Gerstenhauer, F. Hofstadter, M. Landthaler, and W. Stolz Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications Br J Dermatol 144 2001 1154 1160
6. T. Fredriksson, and U. Pettersson Severe psoriasis - oral therapy with a new retinoid Dermatologica 157 1978 238 244
7. P.P. Van Lumig, L.L. Lecluse, R.J. Driessen, P.I. Spuls, J.B. Boezeman, and P.C. van de Kerkhof Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept Br J Dermatol 163 2010 838 846
8. A.B. Gottlieb, R.T. Matheson, N. Lowe, G.G. Krueger, S. Kang, and B.S. Goffe A randomized trial of etanercept as monotherapy for psoriasis Arch Dermatol 139 2003 1627 1632
9. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022
10. K.A. Papp, S. Tyring, M. Lahfa, J. Prinz, C.E. Griffiths, and A.M. Nakanishi A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Br J Dermatol 152 2005 1304 1312
11. S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 2006 29 35
12. S. Armijo-Olivo, S. Warren, and D. Magee Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review Physical Therapy Reviews 14 2009 36 49
13. R. Gniadecki, K. Kragballe, T.N. Dam, and L. Skov Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris Br J Dermatol 164 2011 1091 1096